| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.TP.0000185200.17589.74 |
| P698 | PubMed publication ID | 16314786 |
| P50 | author | Antoine Pariente | Q37830242 |
| P2093 | author name string | Emmanuel Letavernier | |
| Christophe Legendre | |||
| Emmanuel Morelon | |||
| Marie-Noëlle Pe'raldi | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1198-1203 | |
| P577 | publication date | 2005-11-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Proteinuria following a switch from calcineurin inhibitors to sirolimus | |
| P478 | volume | 80 |
| Q85964497 | AKT2 is essential to maintain podocyte viability and function during chronic kidney disease |
| Q38068519 | Adverse events associated with mTOR inhibitors |
| Q38875284 | Autophagy and Tubular Cell Death in the Kidney. |
| Q33810193 | Care of the liver transplant patient |
| Q30419381 | Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin |
| Q37517602 | Considerations in sirolimus use in the early and late post-transplant periods |
| Q80184941 | Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria |
| Q46798712 | Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria |
| Q59507555 | Conversion to Everolimus in Kidney Transplant Recipients: A Safe and Simple Procedure |
| Q43284032 | Conversion to everolimus in kidney transplant recipients with decreased renal function. |
| Q83841668 | Conversion to proliferation signal inhibitors-based immunosuppressive regimen in kidney transplantation: to whom and when? |
| Q26992343 | Corticosteroid and calcineurin inhibitor sparing regimens in kidney transplantation |
| Q38058428 | Current trends in immunosuppressive therapies for renal transplant recipients |
| Q46224052 | Decrease in sirolimus-induced proteinuria after switch to everolimus in a liver transplant recipient with diabetic nephropathy |
| Q44779498 | Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. |
| Q52889823 | Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. |
| Q46986750 | Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria |
| Q53425824 | Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus. |
| Q53603705 | Effect of cyclosporine and sirolimus on the expression of connective tissue growth factor in rat experimental chronic nephrotoxicity. |
| Q53828973 | How often do we face side effects of sirolimus in pediatric renal transplantation? |
| Q54597078 | Indications and effectiveness of the mammalian target of rapamycin in liver transplantation. |
| Q37822152 | Individualizing early use of sirolimus in renal transplantation |
| Q37184425 | Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation |
| Q34362275 | Lipidomic assessment of plasma and placenta of women with early-onset preeclampsia. |
| Q42795561 | Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy |
| Q38002007 | Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications |
| Q37149434 | Mechanisms and management of proteinuria in kidney transplant patients |
| Q42418219 | Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients. |
| Q42555714 | Overview of immunosuppression in liver transplantation |
| Q57151742 | Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation |
| Q37760379 | Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases |
| Q46429375 | Proteinuria and renal transplantation |
| Q34483895 | Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure: An Observational Cohort Study |
| Q53604923 | Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. |
| Q79959715 | Proteinuria in transplant patients associated with sirolimus |
| Q50958523 | Reduction of Slit Diaphragm-associated Molecules by Sirolimus: Is it Enough to Induce Proteinuria? |
| Q43175107 | Replacing calcineurin inhibitors with proliferation signal inhibitors after kidney transplantation: indications, results, and disadvantages |
| Q37356116 | Reviewing the evidence for de novo immunosuppression with sirolimus |
| Q56908156 | Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids |
| Q37779484 | Sirolimus for calcineurin inhibitors in organ transplantation: contra |
| Q33397668 | Sirolimus in pediatric renal transplantation |
| Q43840708 | Sirolimus in renal transplantation: analysis of safety and efficacy in a nonprotocol conversion group |
| Q38922365 | Targeting mTOR Signaling Can Prevent the Progression of FSGS. |
| Q83446861 | The incidence of cancer and potential role of sirolimus immunosuppression conversion on mortality among a single-center renal transplantation cohort of 1,816 patients |
| Q46187860 | Therapeutic effect of Tripterygium wilfordii on proteinuria associated with sirolimus in renal transplant recipients |
| Q37873950 | Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment |
| Q40073855 | Trends in the use of maintenance immunosuppressive drugs among liver transplant recipients in Taiwan: a nationwide population-based study |
| Q79445767 | When should post-transplantation proteinuria be attributed to the renal allograft rather than to the native kidney? |
| Q38209973 | mTOR inhibitors and renal allograft: Yin and Yang. |
| Q38962103 | mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions |
| Q37218125 | mToR inhibitors-induced proteinuria: mechanisms, significance, and management |
Search more.